Cyfuse Biomedical K.K. [4892.T]
TOKYO, Apr 10 (Pulse News Wire) – Cyfuse Biomedical K.K. (4892.T) announced today that its joint project with Hiroshima University to develop innovative periodontal tissue regeneration therapy using bio-3D printing technology has been selected for funding by the Japan Agency for Medical Research and Development (AMED).
This project, which began in fiscal year 2023, aims to address severe periodontitis, a condition affecting approximately 40% of individuals aged 40 and above in Japan. Current treatments struggle to fully cure severe cases, leading to tooth loss and potentially contributing to modern diseases such as diabetes and cardiovascular disorders. Through non-clinical trials, the team confirmed the effectiveness of their approach, presenting findings at eight academic conferences and filing two international patents.
Looking ahead, Cyfuse Biomedical plans to accelerate clinical development through collaboration with Hiroshima University, targeting the establishment of a novel treatment method for severe periodontitis. The goal is to improve quality of life and extend healthy lifespans by preserving natural teeth. The company also intends to expand its regenerative medicine pipeline and explore entry into lifestyle disease areas and global markets.
Details on the impact of this grant on the company's fiscal year ending December 2026 will be disclosed once evaluated.
🟢 Confidence: High AI-translated content.